From PubMed (November 14, 2023)--"Discontinuation of dimethyl fumarate in multiple sclerosis--a nationwide study":
https://pubmed.ncbi.nlm.nih.gov/37956521/The authors conclude that
In this population-based study, we found major differences between the MS clinics in rates and reason for discontinuation of DMF. Our results suggest that management strategies during DMF treatment can reduce discontinuation rates.
Of the experimental subjects, 54.5% stopped taking Tecfidera because of adverse events, and 26.1% stopped taking it because of "active disease." It looks as if Tecfidera hasn't gone over very well, all in all. And the solution to this, the authors suggest, might be better "management strategies."
The MS clinics are probably being told, in effect, that they need to manage their patients on Tecfidera better. I wonder what this means though.
When I've been taking an MS drug (Avonex, Copaxone, Glatopa), the prescribing neurologist just prescribed it and ordered some standard lab work and had very little to say otherwise on the topic. When I wanted to stop the Avonex and later the Copaxone, there was no attempt at persuading me to continue. Would these better management strategies mean that patients wanting to stop an MS drug (like Tecifidera) will be more actively encouraged to stay on it?